Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. - Test2 - elhamkhani - TriplyDB

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

http://www.wikidata.org/entity/Q33821320

about

Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib Molecular biology of lung cancer: clinical implications Clinical use of crizotinib for the treatment of non-small cell lung cancer MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours ErbB receptors: from oncogenes to targeted cancer therapies Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications Afatinib in Non-Small Cell Lung Cancer Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer The distinctive nature of adenocarcinoma of the lung Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Combating acquired resistance to tyrosine kinase inhibitors in lung cancer Ten things you should know about protein kinases: IUPHAR Review 14 Irreversible EGFR-TKIs: dreaming perfection Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Molecular pathology of lung cancer: key to personalized medicine.Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Activating HER2 mutations in HER2 gene amplification negative breast cancer Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma.Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance Novel insights into the molecular origins and treatment of lung cancer

P2860

Q24569706-98A9B375-39A9-44DC-A1FF-8F418F48BAF3 Q24606177-86F6064D-4E43-49D1-BFA1-918CDB3969CE Q24610335-0194B613-4B42-421E-8E8A-DA1F1DD0FF6C Q24630466-98613E30-4113-46C6-B506-8BBE8389A1AE Q24646295-71A8AD18-C8C0-49D6-9604-D2498FC86A39 Q24649549-1057BFA7-D91E-4DF9-A384-E9D625263933 Q24649935-1B663CE9-CF39-4C86-9249-8CAC504B8445 Q24653999-DE9B5D49-916E-4FF2-8210-38BCE88A7B37 Q24683709-67A4A8FF-5812-4E8C-AEEB-D8C90161D86E Q26741318-D4235C91-5911-40D8-813F-36EE3A9A6AA1 Q26749005-AC712BD2-6EEF-4FF0-95B2-C5001D59C314 Q26750428-0D90BC87-38A4-45D3-B93D-3B427D736414 Q26771116-AA019507-8129-405D-8C29-833BC2BD13DF Q26772969-3EB3B2D5-3EE5-4765-9743-A1BB19450341 Q26781159-2C5F1D81-002B-4CA7-A090-F6C9A84479BE Q26795556-AE732949-C39E-4A3F-A765-D555A694927E Q26797297-4F559CC2-A7EA-4A39-9267-681F7DDBB011 Q26823978-55279B17-2E40-4797-9955-4BB462DB4EC7 Q26824877-46637B06-D54D-4443-AD07-C7AD22A3596D Q26849417-EDD62540-85F8-45F5-B530-0403EA3F71BD Q26866186-F801F6B1-98DC-4E50-B8CF-61CB31C26925 Q27014117-A676B5C6-FF08-4509-963C-55E0A1965E19 Q27021203-8184F8A2-095F-48BD-A65A-63A5B282CC1D Q27021738-38924D10-7B13-4DA9-8C65-DF12B43AC004 Q27025863-863A1E66-A9C9-4466-BBF7-17A1AAD27A56 Q27302811-39FF840B-6EAA-411C-A241-254FF1A4CB2F Q27644014-CD8A59F6-84B6-4CDE-AEA2-0F029E7CE49A Q27691299-30DDA58B-B91F-4738-8711-544F89296D5B Q27693185-400FB827-2A0A-4EF0-B81A-76CD6FF06B2B Q27851396-5DF934E8-2BAD-407A-AA12-28AB729EF04F Q27851628-F6116AE3-DE94-4E9B-9DA8-FBCAC1FF2F87 Q27851702-9A5EB66F-BD1D-45D3-86D5-B35D75F18A68 Q27851987-7B6B9503-A12B-4A4C-9CE7-D23F5DBBD423 Q27852553-7284771B-7C4F-42E7-8805-F8EEEAFC6CC1 Q27853221-C30AA6B6-3F26-42EE-AA0A-872AC5132AD7 Q27853391-704EA1B2-DFA2-4F7C-9D18-CCC26D937F5B Q28075704-2C09F599-EF71-488A-93B7-F5EB657B4756 Q28079320-E97EED8E-BE6D-4A99-B1FF-956D74AA5CDB Q28083239-6834C586-A215-4520-9925-395DD9FC86FB Q28386773-86356732-66D5-4FEB-A519-EA478128E28C

P2860

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

http://www.wikidata.org/entity/Q33821320

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@ast

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@en

type

label

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@ast

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@en

prefLabel

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@ast

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@en

P1433

Q33821320-FD9D5680-75A1-45E0-9216-18E69232A857

P1476

Q33821320-BE1D92E0-BC8F-409D-A4E1-CD04F00B8661

P2093

Q33821320-093A9DD7-CDA3-4AD9-AE2B-958658F19069

Q33821320-095C30AE-0A75-469B-B851-15E63D875D29

Q33821320-12BC41C9-EDF2-4DC6-A38C-B7209450257B

Q33821320-1A5F808B-BD3B-44ED-B355-A0C7D452645E

Q33821320-1DB6E40B-7B81-4BBB-8CBF-11A80116E084

Q33821320-24C4FC70-F4F2-47BF-837E-9C6B812E92E4

Q33821320-3188A235-073F-46C9-8926-C15F98D5D247

Q33821320-382075B4-84DC-430B-933D-5CC10088A58A

Q33821320-518DDFA7-5133-426E-A2C3-7B14B253B677

Q33821320-5DD5A128-7ABB-4770-A009-E2DE9827807E

P2860

Q33821320-0ADE7AE0-1D82-4E4D-81EE-C16B54845B36

Q33821320-1378F170-64C8-40E1-93C0-543A5EE85ED7

Q33821320-26585C8B-9F71-4414-8DB3-88162B0D166B

Q33821320-28FFB334-BD37-4165-9720-5F615F46CEAA

Q33821320-337E0402-5151-4947-A6FC-DD44A52D6129

Q33821320-3D8B6508-B333-4097-8901-619E8EED0616

Q33821320-49D1986D-861D-4E59-AC73-82A42317B9E4

Q33821320-536A3870-B820-4027-A554-5C04A55C2BC6

Q33821320-562DE8A0-0154-4C91-8680-246BB53A8FD0

Q33821320-59018749-3BF1-4758-80B2-5BBD0B4A3109

P304

Q33821320-86C43B3F-9A8D-49C0-851A-F067762BF6CB

P31

Q33821320-40BC2C64-EBC4-48B6-932D-CF353328229A

P356

Q33821320-151E4566-4338-4E95-9C9F-6BAE31DB276C

P407

Q33821320-C2D36339-3553-4089-97CF-7E15349CBF96

P433

Q33821320-E4C0683E-102A-40AF-87A8-8FB80E2B5204

P478

Q33821320-ED57CD7F-B68B-47EF-B3A8-FAA5BAA0124B

P577

Q33821320-33685E6B-A049-42EA-B5A3-6788298C52C0

P5875

Q33821320-760B3496-E507-4187-9304-FC2EBDE44593

P698

Q33821320-291601CB-36B4-48B9-8388-CF733DE69D17

P932

Q33821320-A9AE6279-36A6-499D-945C-5371172CD0B6

P356

PNAS.0502860102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Irreversible inhibitors of the ...... uired resistance to gefitinib.

@en

P2093

Allan Wissner

http://www.w3.org/2001/XMLSchema#string

Brian W Brannigan

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

Daphne W Bell

http://www.w3.org/2001/XMLSchema#string

David R Driscoll

http://www.w3.org/2001/XMLSchema#string

Eunice L Kwak

http://www.w3.org/2001/XMLSchema#string

Jeffrey Settleman

http://www.w3.org/2001/XMLSchema#string

John P McGinnis

http://www.w3.org/2001/XMLSchema#string

Kurt J Isselbacher

http://www.w3.org/2001/XMLSchema#string

Nadia Godin-Heymann

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Micronutrient sprinkles to control childhood anaemia

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

P304

7665-7670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0502860102

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7845000

http://www.w3.org/2001/XMLSchema#string

P698

15897464

http://www.w3.org/2001/XMLSchema#string

P932

1129023

http://www.w3.org/2001/XMLSchema#string